Compare GRSD & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRSD | RNTX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.8M | 65.3M |
| IPO Year | 2021 | 2017 |
| Metric | GRSD | RNTX |
|---|---|---|
| Price | $1.85 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 324.7K | ★ 427.7K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $0.69 |
| 52 Week High | $2.41 | $2.18 |
| Indicator | GRSD | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 44.63 |
| Support Level | $1.78 | $0.69 |
| Resistance Level | $2.03 | $0.88 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 7.56 | 19.75 |
Grandstand Ltd is the intelligence layer powering informed decisions for consumers and partners across sports, gaming and entertainment. Its brands include OddsJam, OpticOdds, RotoWire, Gambling.com and Casinos.com. The group's partner solutions span sports data, advertising, audience monetization, entertainment, and tickets.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.